Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sorafenib
Drug ID BADD_D02058
Description Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.
Indications and Usage Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
Marketing Status approved; investigational
ATC Code L01EX02
DrugBank ID DB00398
KEGG ID D08524
MeSH ID D000077157
PubChem ID 216239
TTD Drug ID D0W5HK
NDC Product Code 24979-715; 51407-760; 13668-682; 12527-8488; 63850-8051; 68554-0073; 51990-201; 0378-1201; 0480-5425; 47049-848; 43598-458; 50419-488
UNII 9ZOQ3TZI87
Synonyms Sorafenib | Nexavar | BAY 43-9006 | BAY 43 9006 | BAY 439006 | Sorafenib N-Oxide | Sorafenib N Oxide | BAY-673472 | BAY 673472 | BAY 545-9085 | BAY 545 9085 | BAY 5459085 | BAY-545-9085 | BAY5459085 | Sorafenib Tosylate | 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
Chemical Information
Molecular Formula C21H16ClF3N4O3
CAS Registry Number 284461-73-0
SMILES CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mucosal toxicity12.03.01.056; 08.01.06.0240.000112%Not Available
Internal haemorrhage24.07.01.0720.000616%Not Available
Hemianaesthesia17.02.06.0430.000168%Not Available
End stage renal disease20.01.03.0190.000168%Not Available
Intracranial mass17.11.01.0170.000112%Not Available
Tongue discomfort07.14.02.0190.000246%Not Available
Adrenocortical carcinoma16.24.06.002; 05.01.04.0100.000112%Not Available
Biliary obstruction09.02.02.0050.000280%Not Available
Dilated cardiomyopathy02.04.01.0170.000112%Not Available
Disease complication08.01.03.0870.000168%Not Available
Food refusal19.09.03.003; 14.03.01.0140.000504%Not Available
Gait inability17.02.05.069; 08.01.02.0110.004399%Not Available
Gastrointestinal angiectasia24.03.03.048; 07.15.04.0090.000112%Not Available
Haemoperitoneum24.07.02.065; 12.01.17.007; 07.07.02.0070.000112%Not Available
Hepatic cancer stage IV16.07.02.010; 09.04.02.0170.000224%Not Available
Huerthle cell carcinoma16.24.03.007; 05.02.05.0110.000112%Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.0130.000168%Not Available
Intra-abdominal fluid collection07.07.01.014; 21.07.04.0140.000336%Not Available
Metastases to diaphragm22.09.02.008; 16.22.02.0310.000112%Not Available
Metastases to gallbladder16.22.02.033; 09.04.02.0180.000112%Not Available
Metastases to thyroid05.02.05.012; 16.22.02.0430.000112%Not Available
Myelosuppression01.03.03.0150.000504%Not Available
Oral mucosal roughening07.05.05.0330.000112%Not Available
Plicated tongue07.14.01.0190.000112%Not Available
Poorly differentiated thyroid carcinoma16.24.03.008; 05.02.05.0130.000112%Not Available
Reactive perforating collagenosis23.07.04.0450.000112%Not Available
Skin dystrophy23.01.03.0040.000112%Not Available
Soft tissue neoplasm16.33.08.004; 15.09.02.0080.000112%Not Available
Squamous cell carcinoma of the hypopharynx22.08.02.018; 16.19.10.0010.000112%Not Available
Taste disorder17.02.07.029; 07.14.03.0040.000280%Not Available
The 24th Page    First    Pre   24 25    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene